▶주메뉴 바로가기
▶본문 바로가기
SK Biopharmaceuticals has turned in its best first-quarter earnings — 227.9 billion won ($157 million) in sales and 89.8 billion won in operating profit — as sales of its seizure medicine Cenobamate continued to grow in the US. According to the company, operating profit increased by 94 percent from the previous quarter while jumping about 250 percent from the same period last year. Though the January to March period bore more research and development and marketing costs, the Korean drugmaker str
Samsung Life Science Fund announced Thursday a strategic investment in Cartography Biosciences, an American biotech firm specializing in antibody-based oncology therapies. The partnership aims to speed up the development of novel cancer therapies by leveraging Cartography Biosciences’ antigen discovery and drug development capabilities alongside Samsung’s global expertise in life sciences investment and strategic development. “Cartography Biosciences represents a new generation of biotechnology
Celltrion said Wednesday it posted record first-quarter results, with consolidated revenue of over 1.14 trillion won ($783 million) and operating profit of 321.9 billion won. Revenue rose 36 percent on-year, while operating profit surged 115.5 percent, with the operating margin improving to 28.1 percent. All 11 biosimilar products currently on the market maintained stable revenue streams, while high-margin new products drove growth, with sales from the segment jumping 67 percent on-year. These n
Negotiations between Samsung Biologics and its labor union failed to yield a breakthrough Monday, as both sides remained far apart during government-mediated talks aimed at ending the company’s first full-scale strike. Representatives from management and the union met at a mediation table set up by the Ministry of Employment and Labor at 10 a.m., but failed to reach an agreement by press time. Talks resumed in the afternoon after a roughly two-hour morning session ended without progress. Accordi
Samsung Biologics, the biotech arm of Samsung Group, is grappling with its first-ever general strike, entering its third day Sunday, with a pay standoff with its labor union hardening into a test of the company's labor relations and production stability. The union launched a five-day walkout Friday, demanding a 14 percent average wage increase, a one-time 30 million won ($20,400) cash payout per employee and a bonus equal to 20 percent of operating profit. The company has countered with a 6.2 pe
The future of aviation fuel may turn less on how it is produced than on how its raw materials are collected, according to ReFeed CEO Lee Chung-ho. The company is building a business around used cooking oil -- or what Lee calls "liquid gold" -- an increasingly critical feedstock for sustainable aviation fuel, or SAF. With SAF mandates expanding in Europe and set to begin in Korea in 2027, demand for such feedstocks is expected to increase. "The success of the SAF industry depends not on producing
Samsung Biologics’ growth outlook faces uncertainty as a first-ever strike for the firm raises risks to production and client trust. Samsung Biologics’ labor union has asked for a 14 percent average wage increase, a 30 million won ($20,400) cash payout per worker, and a bonus equivalent to 20 percent of operating profit. The company has reportedly offered a 6.2 percent wage increase. While the two sides have yet to find solid middle ground, the Incheon District Court on Thursday ruled that a str
ViGenCell has been selected to deliver an official oral presentation at this year’s American Society of Clinical Oncology annual meeting next month, becoming the first Korean company to do so regarding clinical studies of a cell therapy. The company said the study's principal researcher, Dr. Jeon Young-woo, will lead the presentation of the results from its Phase 2 clinical study of VT-EBV-N during the 2026 ASCO annual meeting slated from May 29 to June 2 in Chicago. VT-EBV-N is an Epstein-Barr
LG AI Research and Vanderbilt University Medical Center unveiled the results of their joint cancer agentic artificial intelligence research at the American Association for Cancer Research 2026, which is being held in San Diego from Friday to Wednesday. The two sides were to present the findings in a joint session titled “Human-AI cooperation: AI as a decision-making partner for medical professionals,” highlighting how AI can support clinical decision-making. The system, built on LG’s pathology A
Daewoong Pharmaceutical is stepping up efforts to expand the global footprint of Nabota, its high-purity botulinum toxin, as demand for anti-aging treatments rises worldwide. The company launched the Nabota Master Class in 2023 to train overseas medical professionals, as exports of the product gained momentum. Nabota exports reached 193 billion won ($131.1 million) last year, nearly quadrupling from 2021. Originally held in Korea, the program has expanded overseas, with sessions in markets such
Chipotle bets on Korea for first bite of Asia
Samsung vs. LG battle for AI cooling heats up
Musinsa posts record earnings on offline, global expansion
One purchase every 0.9 second: Olive Young foreign sales top W1tr
Samsung, SK hynix tax payments surge 167% on chip boom
SK Chemicals eyes European can-coating market
Sept. 2, 2026
May 7, 2026
May 7, 2026
May 6, 2026
May 4, 2026
May 3, 2026
May 2, 2026
April 27, 2026
April 22, 2026
April 21, 2026
April 19, 2026
